UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~Section 13 ORor Section 15(d) OFof ~~THE~~the

~~SECURITIES~~Securities ~~EXCHANGE~~Exchange ~~ACT~~Act OFof 1934

~~Date of Report (Date of earliest event reported):~~ March 6 11, 2026

Date of Report (Date of earliest event reported)

Drugs Made In America Acquisition II Corp.

(Exact Name of Registrant as Specified in Charter)

Cayman Islands		001-42863		99-1815624
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(~~IRS~~I.R.S. Employer Identification ~~No.~~Number)

1 East Broward Boulevard, Suite 700

1 East Broward Boulevard, Suite 700

Fort Lauderdale, FL

33301

(Address of Principal Executive Offices)

(Zip Code)

Fort Lauderdale, FL 33301

(Address of Principal Executive Offices) (Zip Code)

646-726-7074

(Registrant’s ~~Telephone~~telephone ~~Number~~number, ~~Including Area~~including ~~Code)~~area code:

Not Applicable

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since Last~~since ~~Report~~last report)

Check the appropriate box below if the Form 8-K ~~filing~~ filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one ordinary share, $0.0001 par value, and one right to receive one-tenth of one ordinary share	DMIIU	The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-tenth of one ordinary share	DMIIU	The Nasdaq Stock Market LLC
Ordinary shares, par value $0.0001 per share	DMII	The Nasdaq Stock Market LLC
Rights, each entitling the holder to receive one-tenth of one Ordinary Share	DMIIR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405 ~~of this chapter~~) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 ~~of this chapter~~).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01. ~~Other~~Entry ~~Events~~into a Material Definitive Agreement.

AsOn ~~previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on~~ March 611, 2026, Drugs Made In America Acquisition II II Corp. (the “Company”) ~~announced~~issued ~~that,~~an ~~between~~unsecured convertible note (the ~~completion~~“Bridge ofNote”) ~~its~~to ~~initial~~Alpha ~~public~~Multi Family ~~offering~~Office on(the ~~September~~“Investor”) ~~26,~~in ~~2025~~the ~~and~~principal ~~December 31,~~amount ~~2025~~of $150,000 (the ~~sponsor~~“Bridge toLoan”). ~~the~~The ~~Company~~Bridge Loan ~~made~~represents ~~certain~~an ~~improper~~initial ~~withdrawals~~loan towards a contemplated $1,400,000 financing (the “~~Irregularities~~Convertible Notes Financing”) ~~from~~pursuant to the ~~Company’s~~Letter ~~working capital~~of ~~account~~Intent (“LOI”) described under Item 8. 01 of this Current Report on Form 8-K.

AsThe Bridge Note has a ~~result~~maturity ofdate ~~the~~nine ~~events~~months ~~reported~~from ~~above,~~ the ~~board~~date of ~~directors~~issuance, ofunless ~~the~~earlier ~~Company~~converted ~~immediately~~or ~~took~~credited ~~action~~toward tothe ~~confirm~~definitive ~~that~~financing documents for the ~~Irregularities~~Convertible ~~did~~Notes Financing and does not ~~extend~~bear tointerest. Upon the consummation of the Company’s ~~trust~~initial ~~account~~business combination (the “~~Trust~~Business ~~Account~~Combination”), the ~~and~~outstanding asprincipal amount of ~~today,~~the ~~March~~Bridge 6,Note ~~2026~~may, at the ~~Company~~option isof ~~confirming~~the ~~that~~Investor, ~~approximately~~be converted into shares of the combined entity ~~$507,841,957~~at isa conversion price equal to a 35% discount to the ~~Trust~~market ~~Account~~price of such shares at the time of conversion.

1The Company intends to use the proceeds of the Bridge Loan for accounting expenses, audit expenses and other expenses related to the Business Combination.

~~SIGNATURE~~Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

~~Pursuant~~The toinformation ~~the~~set ~~requirements~~forth ~~of the~~in ~~Securities~~Item ~~Exchange~~1.01 ~~Act~~ of ~~1934,~~this Current ~~the~~Report ~~registrant~~on ~~has~~Form ~~duly~~8-K ~~caused~~regarding ~~this~~the ~~report~~issuance toof bethe ~~signed~~Bridge onNote ~~its~~is ~~behalf~~incorporated herein by ~~the undersigned hereunto duly authorized~~reference.

~~Dated:~~The ~~March~~Bridge 6,Note ~~2026~~represents a direct financial obligation of the Company. The Bridge Note is filed as Exhibit 10.3 hereto and is incorporated herein by reference.

~~DRUGS~~Item ~~MADE IN AMERICA ACQUISITION II CORP~~8.01 ~~By:~~Other ~~/s/ Roger Bendelac Name: Roger Bendelac Title: Chief Executive Officer~~Events

2On March 5, 2026, the Company entered into the LOI with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent to provide financing to the Company through a convertible note investment, subject to the negotiation and execution of definitive documentation. On March 9, 2026, the Company and the Investor entered into an addendum to the LOI which amended certain economic terms of the proposed financing (the “Addendum”). Pursuant to the LOI, as amended by the Addendum, the aggregate amount to be loaned is $1,400,000, of which the $150,000 paid to the Company pursuant to the Bridge Loan will be the first payment.

The remaining $1,250,000 of the proposed convertible notes financing is subject to the negotiation and execution of, a convertible note purchase agreement to be negotiated and finalized by the parties. The Addendum contemplates that $400,000 in aggregate funding will be disbursed to the Company on or prior to March 30, 2026.

The foregoing description of the LOI, Addendum and Bridge Note is not complete and is qualified in its entirety by reference to the full text of the LOI, Addendum and Bridge Note, copies of which are filed hereto as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
10.1		Letter of Intent dated March 5, 2026 between Drugs Made in America Acquisition II Corp. and Alpha Multi Family Office
10.2		Addendum to Letter of Intent dated March 9, 2026
10.3		Bridge Financing Convertible Promissory Note dated March 11, 2026
104		Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 17, 2026

	DRUGS MADE IN AMERICA ACQUISITION II CORP.

	By:	/s/ Roger Bendelac
	Name:	Roger Bendelac
	Title:	Chief Executive Officer

Filing Compare · Drugs Made In America Acquisition II Corp.